The Fort Worth Press - Ketamine pill treats depression without psychedelic effects: study

USD -
AED 3.6725
AFN 62.999805
ALL 81.919985
AMD 369.022152
ANG 1.790403
AOA 917.500438
ARS 1429.5006
AUD 1.418611
AWG 1.8025
AZN 1.69565
BAM 1.687089
BBD 2.017174
BDT 122.938906
BGN 1.69088
BHD 0.377743
BIF 2994.099786
BMD 1
BND 1.284073
BOB 6.920735
BRL 5.057098
BSD 1.001557
BTN 94.807122
BWP 13.437361
BYN 2.772827
BYR 19600
BZD 2.014241
CAD 1.401715
CDF 2321.00002
CHF 0.795885
CLF 0.022625
CLP 890.450145
CNY 6.76055
CNH 6.76294
COP 3491.5
CRC 455.637457
CUC 1
CUP 26.5
CVE 95.398186
CZK 20.86645
DJF 178.341147
DKK 6.45693
DOP 58.450255
DZD 133.157039
EGP 50.419299
ERN 15
ETB 159.494926
EUR 0.863803
FJD 2.216895
FKP 0.746148
GBP 0.74675
GEL 2.644999
GGP 0.746148
GHS 11.225023
GIP 0.746148
GMD 72.501494
GNF 8775.000164
GTQ 7.634911
GYD 209.537036
HKD 7.832725
HNL 26.720198
HRK 6.508194
HTG 130.901343
HUF 302.603502
IDR 17742
ILS 2.917604
IMP 0.746148
INR 94.664799
IQD 1310
IRR 1375752.497294
ISK 124.73943
JEP 0.746148
JMD 158.757133
JOD 0.709038
JPY 160.2955
KES 129.460293
KGS 87.4502
KHR 4010.000103
KMF 425.000176
KPW 900.00035
KRW 1512.409963
KWD 0.30839
KYD 0.834674
KZT 490.263143
LAK 22024.999647
LBP 89549.999817
LKR 333.00411
LRD 182.175009
LSL 16.219472
LTL 2.95274
LVL 0.60489
LYD 6.380431
MAD 9.27225
MDL 17.421534
MGA 4204.999974
MKD 53.239641
MMK 2099.090156
MNT 3576.689019
MOP 8.081808
MRU 40.059501
MUR 47.240213
MVR 15.450241
MWK 1736.999524
MXN 17.231399
MYR 4.064897
MZN 63.910222
NAD 16.219781
NGN 1358.999993
NIO 31.619968
NOK 9.565801
NPR 151.694838
NZD 1.722395
OMR 0.384498
PAB 1.001488
PEN 3.406499
PGK 4.359026
PHP 60.386501
PKR 278.325044
PLN 3.67206
PYG 6132.175158
QAR 3.643503
RON 4.523973
RSD 101.405141
RUB 72.448447
RWF 1514.5
SAR 3.752194
SBD 8.065041
SCR 12.521479
SDG 600.50029
SEK 9.41695
SGD 1.28349
SHP 0.746601
SLE 24.749735
SLL 20969.503664
SOS 571.497614
SRD 37.51797
STD 20697.981008
STN 21.375
SVC 8.763273
SYP 110.532098
SZL 16.22018
THB 32.564499
TJS 9.284125
TMT 3.5
TND 2.912023
TOP 2.40776
TRY 46.2995
TTD 6.798097
TWD 31.5805
TZS 2624.998017
UAH 44.900392
UGX 3720.444763
UYU 40.61969
UZS 11999.999956
VES 591.77565
VND 26295.5
VUV 119.50104
WST 2.743493
XAF 565.843581
XAG 0.014405
XAU 0.000232
XCD 2.70255
XCG 1.805015
XDR 0.703697
XOF 564.502097
XPF 102.450395
YER 238.60685
ZAR 16.225025
ZMK 9001.202064
ZMW 17.605527
ZWL 321.999592
  • CMSC

    0.0100

    22.34

    +0.04%

  • CMSD

    0.0600

    22.32

    +0.27%

  • NGG

    -0.2700

    81.57

    -0.33%

  • RBGPF

    2.1500

    62.87

    +3.42%

  • VOD

    -0.5300

    15

    -3.53%

  • BCE

    -0.2369

    24.04

    -0.99%

  • BCC

    0.4500

    71.59

    +0.63%

  • RIO

    0.5400

    105.89

    +0.51%

  • RYCEF

    1.0700

    18.11

    +5.91%

  • GSK

    -0.8100

    52.23

    -1.55%

  • RELX

    -0.9000

    32.84

    -2.74%

  • BTI

    -1.2600

    61.06

    -2.06%

  • JRI

    0.1135

    12.78

    +0.89%

  • AZN

    -1.4800

    177.27

    -0.83%

  • BP

    -1.1900

    41.59

    -2.86%

Ketamine pill treats depression without psychedelic effects: study
Ketamine pill treats depression without psychedelic effects: study / Photo: © AFP/File

Ketamine pill treats depression without psychedelic effects: study

A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.

Text size:

First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".

However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.

In many countries, ketamine has been prescribed for depression for years.

US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".

The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.

Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.

There are also fears that medical use of the drug could slide into abuse.

The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.

"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.

"I don't think these tablets would appeal to people who are abusing ketamine."

- Electro-shock alternative -

The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.

More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.

Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.

Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.

Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.

"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.

This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.

But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".

- Fears of 'opioid style crisis' -

Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.

Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.

US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.

One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.

But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.

By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.

There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.

More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.

X.Silva--TFWP